Insights

Washington, D.C. – July 22, 2026 – Crowell & Moring LLP today shared results from its firmwide integration of Legora as a collaborative AI platform. Crowell has realized significant gains in opportunities to deliver for clients across practices and jurisdictions.  

Washington – July 15, 2026: Crowell & Moring has added Google’s former Regulatory Affairs Counsel for Global Legislative Oversight, James Bair, as a partner and Head of Congressional Investigations in the White Collar and Regulatory Enforcement practice in Washington, D.C. 

Washington – July 8, 2026: Steve Raptis, a Chambers-ranked insurance recovery attorney with more than 30 years of experience representing policyholders, has joined Crowell & Moring as a partner in Washington, D.C., further bolstering the firm’s growing insurance recovery practice. Raptis’s arrival enhances the firm’s robust capabilities in representing policyholder clients in complex and high-stakes insurance disputes.

As federal and state regulators alike continue to tout holding health care organizations accountable for alleged fraud, waste, and abuse as a top priority, ensuring compliance and minimizing enforcement risk has never been more imperative — or more challenging. Health care organizations operate at the intersection of rapid technological changes and within an increasingly complex regulatory landscape, where the rules governing scrutinized areas such as privacy, AI, billing integrity, and strategic transactions are being written, rewritten, and enforced in real time. Treating compliance as a periodic documentation exercise is simply not an option. Today, an effective risk mitigation strategy must be grounded in two complementary elements: a thorough understanding of evolving regulatory obligations and a candid internal assessment of potential points of exposure.

In June 2026, federal regulators and lawmakers continued their efforts to improve drug affordability through targeted reforms. These recent developments will primarily impact pharmaceutical manufacturers, managed care organizations, and pharmacy benefit managers (PBM) serving Medicare Part D program members. PBMs, Medicare Advantage organizations, and Part D sponsors should monitor these changes in the interest of maintaining compliance and providing input on regulatory proposals that may influence their business operations or compensation structures in the future.

Two significant recent developments illustrate the Trump administration’s increasing focus on policing of hospital contracting practices that limit health plan network design flexibility. On June 16, 2026, the U.S. Department of Justice (DOJ) Antitrust Division and Ohio attorney general filed a proposed consent decree resolving their civil antitrust suit against OhioHealth. (Prior Alert) Two days later, the White House Council of Economic Advisers (CEA) released a memorandum quantifying the potential economic effects of a broader ban on the types of contracting restrictions at issue in the OhioHealth case and the DOJ's parallel suit against NewYork-Presbyterian. This alert updates our prior coverage of the OhioHealth complaint and summarizes both developments.

Join us for an interactive and educational event tailored for biotech leaders seeking to ensure security compliance while leveraging the power of Amazon Web Services (AWS). This session will dive into the critical elements of designing secure, scalable, and compliant systems for biotech operations, from research and development to clinical trials and beyond.

The landscape of AI governance and regulation is shifting. Following the release of the White House’s “America’s AI Action Plan” in July 2025 and the President’s signing of related Executive Orders, the White House has emphasized (at least rhetorically) a preference for innovation, adoption, and deregulation. But that does not tell the entire story. The Administration remains committed to exercising a heavy hand in AI, including by banning the U.S. government’s procurement of so-called “woke AI,” intervening in the development of data centers and the export of the AI technology stack, imposing an export fee for certain semiconductors to China, and assuming a stake in a U.S. semiconductor company. State legislatures are also racing to implement their own regulations, particularly around AI’s use in critical areas, such as healthcare, labor and employment, and data privacy. The many sources of regulation raise the specter of a fragmented compliance environment for businesses. This webinar will delve into the Administration’s AI strategy, going beyond the headlines to analyze:

Host Megan Beaver talks to Alex Lucas and Jason Mayer about the No Surprises Act, a 2021 law designed to protect patients from unexpected medical bills, the federal independent dispute resolution process it created, the challenges that have plagued that process, and the new federal rule issued on June 4, 2026. The episode also covers the growing wave of enforcement litigation and what’s on the horizon for IDR.

This podcast episode features the following speakers:

Click below to listen or access from one of these links: PodBean | SoundCloud | iTunes